Chemotherapy and molecular targeted therapy for small intestine cancer

Neoplasms of the small intestine have no specific features at early stage，and the prognosis is poor. The 5 year survival rate of all the patients is about 30% and the middle survival time is 19 months. The retrospective analysis shows that adjuvant chemotherapy after surgical resection might improve the disease free survival while the overall survival is not improved obviously. The patients who are at advanced stage or have regional lymph node metastasis may obtain benefits from adjuvant chemotherapy. Palliative chemotherapy may improve progress free survival and overall survival of patients who are at advanced stage. The therapeutic effect of patients at advanced stage using FOLFOX regimen（5 fluorouracil，calcium folinate and oxaliplatin）is better compared with other regimens. The molecular targeted therapy of small intestine cancer is still in the study process and advanced studies are also needed for chemotherapy.